Telix Pharmaceuticals reported a 19% increase in revenue for its third quarter of 2026, driven by sales of Illuccix and Gozellix, its kits for prostate-specific membrane antigen (PSMA)-PET imaging.
For the period (end-September 30), Telix had group revenues of $245 million, up from $206 million in the same period last year. Precision Medicine revenue, primarily from Illuccix and Gozellix, rose 30% to $201 million from $155 million. Revenue from Telix Manufacturing Solutions, mostly from RLS Radiopharmacies, fell 6% to $44 million from $47 million.
Among quarterly highlights, Telix noted U.S. Food and Drug Administration (FDA) approval of Pixclara (F-18 floretyrosine) for glioma imaging, with the first commercial doses given in September. Telix also agreed to acquire Isotope Technologies Munich (ITM) for $1.65 billion upfront, with shareholders expected to vote on the deal on December 1, the firm said.
